Ribociclib is an orally active, highly selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6. It is the second CDK 4/6 inhibitor approved for hormone receptor–positive breast cancer. The addition of ribociclib to an aromatase inhibitor has resulted in marked improvements in progression-free survival for patients with metastatic breast cancer. Clin Cancer Res; 24(13); 2981–3. ©2018 AACR.
See related article by Shah et al., p. 2999
https://ift.tt/2tQy46G
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου